Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA)

Inclusion Criteria: * at least 18 years of age * symptomatic restenosis in bare metal stent implanted in native coronary artery * angina pectoris * ischemia evidenced by non-invasive diagnostic tests * angiographically evidenced in-stent restenosis \> 50% assessed by quantitative coronary angiography (QCA) * vessel diameter \> 2,5 mm Clinical exclusion criteria: * myocardial infarction within less than past 72 hours * heart failure with left ventricular ejection fraction (LVEF) \< 30% * chronic renal failure with significant impairment of glomerular filtration (creatinine \> 2 mg/dl) * hypersensitivity or contraindication to acetylsalicylic acid, clopidogrel, heparin, abciximab, rapamycin, paclitaxel * hypersensitivity to contrast * other diseases that may cause significant deterioration in long-term prognosis * acute or chronic inflammatory diseases * patients who are unwilling to consent for participation in the study Angiographic exclusion criteria: * significant stenosis in left main coronary artery (LM) * multivessel disease qualifying for coronary artery bypass grafting (CABG) * anatomical localization and morphology that preclude optimal percutaneous intervention intervention's (PCI) result or intravascular ultrasound (IVUS) or optical coherence tomography performance * vessel diameter \< 2,5 mm * restenotic lesion length \> 30 mm